The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 701–800 of 1,043
GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56
Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease
Mantile, F., & Prisco, A. (2020) · Biology · doi:10.3390/biology9120425 · Cited by 56
“Transient brain edema was observed in around 20% of patients, mostly ApoE4 carriers, was dose-dependent, but produced no symptoms in 65% of cases and was resolved in all cases; therefore, the safety and tolerability were considered acceptable [30].”
BackgroundMethodInfluentialMcDade, E. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001131 · Cited by 64
Hajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 63
Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations
Cadiz, M. P., Gibson, K. A., Todd, K. T., Nascari, D. G., Massa, N., Lilley, M. T., Olney, K. C., Al-Amin, M. M., Jiang, H., Holtzman, D. M., et al. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20231363 · Cited by 55
Mandal, P. K., Roy, R. G., & Samkaria, A. (2022) · ACS Omega · doi:10.1021/acsomega.2c02760 · Cited by 60
Wu, Y., Zhang, T., Li, X., Wei, Y., Li, X., Wang, S., Liu, J., Li, D., Wang, S., & Ye, T. (2022) · Theranostics · doi:10.7150/thno.76133 · Cited by 62
“Nevertheless, the highly anticipated Aβ clearance immunotherapy was defeated in recent clinical trials because of the complexity of the AD mechanism [10], indicating the urgent need for a novel Aβ clearance strategy.”
BackgroundEarly- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?
Valdez-Gaxiola, C. A., Rosales-Leycegui, F., Gaxiola-Rubio, A., Moreno-Ortíz, J. M., & Figuera, L. E. (2024) · Diseases · doi:10.3390/diseases12060110 · Cited by 65
“Aducanumab captures aggregated A β and indirectly supports clearance likely by presenting it to microglia for phagocytosis, thereby Monoclonal antibodies (mAbs) against tau proteins are designed to bind to extracellular tau proteins. increasing the β [113].”
BackgroundBeta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease
Moussa, C. E.-H. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1369527 · Cited by 53
Alzheimer's disease: Only prevention makes sense
Viña, J., & Sanz‐Ros, J. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13005 · Cited by 57
Ceyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 51
Molecular Imaging Approaches in Dementia
Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 50
“The bias associated with SUVR is likely to be even more marked when used in clinical trials with disease-modifying agents with PET ligands as surrogate markers (32,34).”
MethodResultTargeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression
Koh, H., Lee, S., Lee, H., Min, J.-W., Iwatsubo, T., Teunissen, C., Cho, H.-J., & Ryu, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313136 · Cited by 53
Presenilin/γ-Secretase Activity Is Located in Acidic Compartments of Live Neurons
Maesako, M., Houser, M. C. Q., Turchyna, Y., Wolfe, M. S., & Berezovska, O. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-21.2021 · Cited by 55
γ-Secretase and its modulators: Twenty years and beyond
Xia, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.011 · Cited by 54
León, B. E., Kang, S., Franca-Solomon, G., Shang, P., & Choi, D. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.778456 · Cited by 65
“In patients with prodromal or mild AD, aducanumab also slowed cognitive decline in a phase 1b clinical trial (Sevigny et al., 2016).”
BackgroundACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecìć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 56
Kaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 59
Clinical considerations in early-onset cerebral amyloid angiopathy
Banerjee, G., Collinge, J., Fox, N. C., Lashley, T., Mead, S., Schott, J. M., Werring, D. J., & Ryan, N. S. (2023) · Brain · doi:10.1093/brain/awad193 · Cited by 62
Mundada, N. S., Rojas, J. C., VandeVrede, L. A., Thijssen, E. H., Iaccarino, L., Okoye, O., Shankar, R. P., Soleimani‐Meigooni, D. N., Lago, A. L., Miller, B. L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01302-w · Cited by 59
“We aimed to further characterize the relationship between tau-PET and plasma p-tau by focusing on these markers in amyloid-PET-positive patients at the early clinical stages of AD—similar to patients included in multiple clinical trials [15, 16].”
Hadipour, M., Kaka, G., Bahrami, F., Meftahi, G. H., Jahromi, G. P., Mohammadi, A., & Sahraei, H. (2018) · Synapse · doi:10.1002/syn.22026 · Cited by 56
“AD, is the most prevalent cause of dementia, which neurodegeneration in specific brain areas cause a decrease in memory and other cognitive abilities (Sevigny et al., 2016).”
Du, H., Liu, X., Xie, J., & Ma, F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00699 · Cited by 55
Kuo, Y.-C., Chen, C.-L., & Rajesh, R. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.065 · Cited by 54
Texture descriptors and voxels for the early diagnosis of Alzheimer’s disease
Nanni, L., Brahnam, S., Salvatore, C., & Castiglioni, I. (2019) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2019.05.003 · Cited by 59
Li, F., Zhan, C., Dong, X., & Wei, G. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp01913a · Cited by 57
Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties
Siddiqui, A., Shah, Z., Jahan, R. N., Othman, I., & Kumari, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112250 · Cited by 59
Gurevich, P., Stuke, H., Kastrup, A., Stuke, H., & Hildebrandt, H. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00114 · Cited by 53
“While the global number of patients with Alzheimer’s disease (AD) is increasing, recent clinical trials suggest for the first time the possibility of devising a disease-modifying treatment (among others, Sevigny et al., 2016).”
BackgroundDhage, P. A., Sharbidre, A. A., Dakua, S. P., & Balakrishnan, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111634 · Cited by 54
NAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
“Unfortunately, most of the trials were either unsuccessful or did not show a dramatic improvement in AD pathology [219,220].”
BackgroundmiRNAs as Therapeutic Tools in Alzheimer’s Disease
Lee, C. Y., Ryu, I. S., Ryu, J., & Cho, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313012 · Cited by 62
“significant clinical effects were reported [42,43,45].”
BackgroundPassive Alzheimer’s immunotherapy: A promising or uncertain option?
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Alavi, A. A., Kepp, K. P., Sensi, S. L., Perry, G. L., Robakis, N. K. R. K., Barrio, J. R., & Vissel, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101996 · Cited by 56
Prognostic and Predictive Factors in Early Alzheimer’s Disease: A Systematic Review
Garcia, M. J., Leadley, R. M., Ross, J., Bozeat, S., Redhead, G., Hansson, O., Iwatsubo, T., Villain, N., & Cummings, J. L. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230045 · Cited by 56
Treating Alzheimer’s disease using nanoparticle-mediated drug delivery strategies/systems
Roghani, A. K., Garcia, R. I., Roghani, A., Reddy, A. P., Khemka, S., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102291 · Cited by 59
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, M. W., Kanoria, S., Miller, M. J., Aisen, P. S. S., Beckett, L. A., Conti, C., Diaz, A., Flenniken, D., Green, R. C., Harvey, D. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14321 · Cited by 65
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 68
Reiman, E. M. (2016) · Nature · doi:10.1038/537036a · Cited by 61
Chang, J. L., Hinrich, A. J., Roman, B., Norrbom, M., Rigo, F., Marr, R. A., Norstrom, E. M., & Hastings, M. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.029 · Cited by 61
Comparison of Blood Lead Levels in Patients With Alzheimer’s Disease and Healthy People
Fathabadi, B., Dehghanifiroozabadi, M., Aaseth, J., Sharifzadeh, G., Nakhaee, S., Rajabpour-Sanati, A., Amirabadizadeh, A., & Mehrpour, O. (2018) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317518794032 · Cited by 51
Cho, H., Sharma, A. K., Zhang, Y., Gross, M. L., & Mirica, L. M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00114 · Cited by 59
Schulz, J. B., Cookson, M. R., & Hausmann, L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13844 · Cited by 52
Personalised Medicine, Individual Choice and the Common Good
van Beers, B. C., Dickenson, D. L., & Sterckx, S. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108590600 · Cited by 64
Targeting gut microbiota to alleviate neuroinflammation in Alzheimer’s disease
Nguyen, V. T. T., & Endres, K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114418 · Cited by 61
Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model
Kong, C., Yang, E.-J., Shin, J., Park, J., Kim, S.-H., Park, S.-W., Chang, W. S., Lee, C.-H., Kim, H., Kim, H.-S., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00333-x · Cited by 47
“Recently, the FDA approved Adu for the treatment of AD based on an evaluation of effects of the drug in clinical stages [5, 40].”
BackgroundResultInfluentialA review of harmonization strategies for quantitative PET
Akamatsu, G., Tsutsui, Y., Daisaki, H., Mitsumoto, K., Baba, S., & Sasaki, M. (2023) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01820-x · Cited by 57
“[64] reported that Aducanumab, a human monoclonal antibody that selectively accumulates with Aβ aggregates, reduced Aβ plaques with amyloid PET as an adjunct marker for Aβ pathology.”
BackgroundBiopharmaceutical applications of microbial polysaccharides as materials: A Review
Song, Y., Li, S., Hao, G., Yip, R. C. S., & Chen, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124259 · Cited by 56
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 58
Shaw, A. E., & Bamburg, J. R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.031 · Cited by 55
“Interim results from double blind studies have suggested aducanumab reduces plaques and Aβ in human and AD mouse brain and slows somewhat the cognitive decline in humans (Sevigny et al., 2016).”
Doan, N. T., Engvig, A., Persson, K., Alnæs, D., Kaufmann, T., Rokicki, J., Córdova‐Palomera, A., Moberget, T., Brækhus, A., Barca, M. L., et al. (2017) · Scientific Reports · doi:10.1038/srep45131 · Cited by 57
The emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 50
Mechanisms of Risk Reduction in the Clinical Practice of Alzheimer’s Disease Prevention
Schelke, M. W., Attia, P., Palenchar, D. J., Kaplan, B., Mureb, M., Ganzer, C. A., Scheyer, O., Rahman, A., Kachko, R., Krikorian, R., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00096 · Cited by 56
“Aducanumab and solanezumab (AAIC 2017, AD/PD 2017) have successfully reduced amyloid burden in humans (Sevigny et al., 2016) and solanezumab is the trial agent in an AD prevention trial (the A4 study) (Sperling et al., 2014).”
BackgroundAmyloid-Beta Solubility in the Treatment of Alzheimer’s Disease
Murphy, M. P. (2018) · New England Journal of Medicine · doi:10.1056/nejme1714638 · Cited by 53
Current landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Correa, D., Scheuber, M. I., Shan, H., Weinmann, O., Baumgartner, Y. A., Harten, A., Wahl, A.-S., Skaar, K., & Schwab, M. E. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200057120 · Cited by 52
Emerging ocular biomarkers of Alzheimer disease
van Wijngaarden, P., Hadoux, X., Alwan, M., Keel, S., & Dirani, M. (2017) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12872 · Cited by 52
“Brain vasogenic edema occurred in a dose-dependent manner and was observed in 47% of subjects treated with the highest dose of the antibody.(11) Long-term extension of the study and 2 phase III clinical trials are underway.”
BackgroundHarn, N. R., Hunt, S. L., Hill, J., Vidoni, E. D., Perry, M., & Burns, J. M. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001693 · Cited by 55
“Reliable detection of amyloid-β plaque before cognitive decline may be important, as new clinical treatment strategies that are currently in development that may disrupt or remove these plaques.(13) It is our experience that in patients with extensive plaque deposition, the visual interpretation of amyloid-β PET scans…”
Cao, Y., Jiang, X., & Han, W. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00803 · Cited by 52
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Selles, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179925 · Cited by 50
Meier, S. R., Syvänen, S., Hultqvist, G., Fang, X. T., Roshanbin, S., Lannfelt, L., Neumann, U., & Sehlin, D. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213140 · Cited by 54
“Aducanumab, which targets A b aggregates, recently showed benefits in AD patients ( 3 ), and BAN2401 ( 4 ), the humanized version of mAb158 ( 5,6 ), which targets soluble A b protofibrils, is in a phase 2b clinical trial.”
A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease
Lin, C., Huang, C., Huang, K., Lin, K., Yen, T., & Kuo, H. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.726 · Cited by 57
“The prodromal stage of AD provides a window of opportunity for treatment to delay the onset of the disease and slow the progress of neurodegeneration.(6,7) Thus, diagnostic methods for the disease during the prodromal stage are important.”
Diagnostic Biomarkers for Alzheimer’s Disease Using Non-Invasive Specimens
Paraskevaidi, M., Allsop, D., Karim, S., Martin, F. L., & Crean, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061673 · Cited by 53
“With the emergence of promising drug candidates for the treatment of AD [18], it is anticipated that an early diagnosis is likely to define the course of the disease as administration of a candidate treatment is expected to be most effective if provided as early as possible [10,19–21] (i.”
BackgroundTherapeutic potential of a TrkB agonistic antibody for Alzheimer's disease
Wang, S., Yao, H., Xu, Y., Hao, R., Zhang, W., Liu, H., Huang, Y., Guo, W., & Lu, B. (2020) · Theranostics · doi:10.7150/thno.44165 · Cited by 53
“Given that the reduction in Aβ plaques level by the BDNF was mild (less than 20%), it is less likely that such a reduction would help improve cognition when compared with those by Aβ antibodies [92-94].”
ResultSu, L., Wang, N., Han, J., & Shen, Y. (2021) · The Neuroscientist · doi:10.1177/10738584211021018 · Cited by 59
Overview of therapeutic targets in management of dementia
Malik, R., Kalra, S., Bhatia, S., Al‐Harrasi, A., Singh, G., Mohan, S., Makeen, H. A., Albratty, M., Meraya, A. M., Bahar, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113168 · Cited by 56
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine
Iannone, L. F., Cesaris, F. D., Ferrari, A., Benemei, S., Fattori, D., & Chiarugi, A. (2022) · Cephalalgia · doi:10.1177/03331024221111526 · Cited by 54
“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50
Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
Bittar, A., Sengupta, U., & Kayed, R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0046-8 · Cited by 50
“Aducanumab was shown to decrease soluble and fibrillar forms of Aβ in several brain regions associated with cognitive decline (such as frontal and parietal cortices, posterior cingulate cortex, lateral temporal, and sensorimotor cortex, as well as anterior cortex), and slow down cognitive decline in clinical dementia…”
BackgroundRofo, F., Buijs, J., Falk, R., Honek, K., Lannfelt, L., Lilja, A. M., Metzendorf, N. G., Gustavsson, T., Sehlin, D., Söderberg, L., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00258-x · Cited by 59
Current understanding of metal-dependent amyloid-β aggregation and toxicity
Yi, Y., & Lim, M. H. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00208f · Cited by 53
C3N nanodots inhibits Aβ peptides aggregation pathogenic path in Alzheimer’s disease
Yin, X., Zhou, H., Zhang, M., Su, J., Wang, X. L., Li, S., Yang, Z., Kang, Z., & Zhou, R. (2023) · Nature Communications · doi:10.1038/s41467-023-41489-y · Cited by 57
“Besides, other anti-AD agents (including peptides 19,20 , polymers 21,22 , small drug molecules 23 – 26 , and metal oxides 27 ) show only a very mild inhibition effect on A β peptides aggregation.”
Chimeric antigen receptor macrophages target and resorb amyloid plaques
Kim, A. B., Xiao, Q., Yan, P., Pan, Q., Pandey, G., Grathwohl, S., Gonzales, E. R., Xu, I., Cho, Y., Haecker, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175015 · Cited by 55
“Our A β CAR construct contains an extracellular binding domain derived from the aducanumab antibody, which is known to preferentially bind aggregated forms of A β , including oligomers and fibrils (19).”
BackgroundKršek, A., & Batičić, L. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4020020 · Cited by 65
“All cortical brain areas studied have shown Aducanumab to dramatically reduce amyloid, despite ongoing doubts about its therapeutic usefulness [89,90].”
BackgroundA Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?
Beach, T. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0072-x · Cited by 57
“Perhaps most disappointing has been the disconnect between plaque load reduction and cognitive improvement [49], thus far denying amyloid PET true surrogate status, although the Phase 1b aducanamab trial of 125 subjects offers hope of achieving this in subsequent trials [50].”
BackgroundRosenberg, R. N., Fu, M., & Lambracht-Washington, D. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0441-4 · Cited by 48
The biogenesis and biology of amyloid β oligomers in the brain
Ashe, K. H. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12084 · Cited by 54
Zhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49
“21 Based on the results of the PRIME trial, two clinical trials, EMERGE (NCT02484547) and ENGAGE (NCT02477800) trials, were initiated in 2015, both of which were phase III studies conducted over 18 months in individuals with prodromal and mild AD.”
MethodTu, L. M. T. P. P. L. M., Hoang, T. X., Thu, V. T. A., Pham, H. L., Le, H. T. N., Chinnadayyala, S. R., Kim, J. Y., Lee, S.-M., Cho, W. W., Kim, Y. H., et al. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1887732 · Cited by 53
Physiological clearance of Aβ by spleen and splenectomy aggravates Alzheimer‐type pathogenesis
Yu, Z., Chen, D., Tan, C., Zeng, G., He, C.-Y., Wang, J., Bu, X., & Wang, Y. (2021) · Aging Cell · doi:10.1111/acel.13533 · Cited by 57
The advent of Alzheimer treatments will change the trajectory of human aging
Selkoe, D. J. (2024) · Nature Aging · doi:10.1038/s43587-024-00611-5 · Cited by 57
“54,55).”
Doens, D., Valiente, P. A., Mfuh, A. M., Vo, A. X. T., Tristan, A., Carreño, L., Quijada, M. R., Nguyen, V. T., Perry, G. L., Larionov, O. V., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00386 · Cited by 53
Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606
Wagner, S. L., Rynearson, K. D., Duddy, S. K., Zhang, C., Nguyen, P. D., Becker, A., Vo, U., Masliah, D., Monte, L., Klee, J. B., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240861 · Cited by 49
“…and statistically significant reduction in cognitive decline as measured by MiniMentalStateExaminationandClinicalDementiaRating, relative to placebo, lending significant support to therapeutic strategies targeting plaque-associated Ab peptides for the treatment of AD (Sevigny et al., 2016).”
BackgroundEvaluation of Cholinergic Deficiency in Preclinical Alzheimer’s Disease Using Pupillometry
Frost, S. M., Robinson, L., Rowe, C. C., Ames, D. J., Masters, C. L., Taddei, K., Rainey‐Smith, S. R., Martins, R. N., & Kanagasingam, Y. (2017) · Journal of Ophthalmology · doi:10.1155/2017/7935406 · Cited by 54
Polyphenols Derived from Lychee Seed Suppress Aβ (1-42)-Induced Neuroinflammation
Tang, Y., Xiong, R., Wu, A., Yu, C., Zhao, Y., Qiu, W., Wang, X., Teng, J., Liu, J., Chen, H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072109 · Cited by 52
“Senile plaques (SPs) and neurofibrillary tangles (NFTs) are Int.”
BackgroundInfluentialMultidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status
Delrieu, J., Payoux, P., Carrié, I., Cantet, C., Weiner, M., Vellas, B., & Andrieu, S. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.008 · Cited by 45
“Recent results of a phase Ib study evaluating the impact of aducanumab on brain amyloid burden and cognitive parameters (Mini-Mental State Examination [MMSE] and Clinical Dementia Rating [CDR]) are promising and appear to validate the use of amyloid biomarker assessment in preventive therapy trials [5].”
BackgroundIn vivo Retinal Fluorescence Imaging With Curcumin in an Alzheimer Mouse Model
Sidiqi, A. M., Wahl, D. J., Lee, S., Ma, D., To, E., Cui, J. Z., To, E. C., Beg, M. F., Šarunic, M. V., & Matsubara, J. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00713 · Cited by 52
Alzheimer’s Disease: Drug Discovery
(2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 44
Petrushina, I., Hovakimyan, A., Harahap-Carrillo, I. S., Davtyan, H., Antonyan, T., Chailyan, G., Kazarian, K., Antonenko, M., Jullienne, A., Hamer, M. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104823 · Cited by 48
“This is regrettable, because the dose-dependent effectiveness of passively administered anti-Aβ antibodies specific to oligomers/protofibrils, was recently demonstrated in subjects with mild AD (Bachmann, 2019; Neurimmune, 2015; Selkoe, 2018; Sevigny et al., 2016).”
BackgroundInfluentialJoseph‐Mathurin, N., Llibre‐Guerra, J. J., Li, Y., McCullough, A. A., Hofmann, C., Wojtowicz, J., Park, E., Wang, G., Preboske, G. M., Wang, Q., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26511 · Cited by 47
Self-citationThe role of histidines in amyloid β fibril assembly
Brännström, K., Islam, T., Sandblad, L., & Olofsson, A. (2017) · FEBS Letters · doi:10.1002/1873-3468.12616 · Cited by 54
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Schilling, S., Rahfeld, J.-U., Lues, I., & Lemere, C. A. (2018) · Molecules · doi:10.3390/molecules23051068 · Cited by 45
“A very prominent example for that is provided by a phase 1b study of aducanumab [26].”
BackgroundAlzheimer’s Disease Model System Using Drosophila
Tsuda, L., & Lim, Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0529-0_3 · Cited by 50
IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?
Kronimus, Y., Dodel, R. C., Galuska, S. P., & Neumann, S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.006 · Cited by 53
Progress of Pharmacological Approaches in Parkinson's Disease
Zeuner, K. E., Schäffer, E., Hopfner, F., Brüggemann, N., & Berg, D. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1374 · Cited by 51
“In a recent clinical trial of Alzheimer’s disease, cognitive decline could be significantly slowed down in antibodytreated patients as opposed to the placebo group.(52) Antibodies in PD target the rogue protein aSYN, which is accessible in the extracellular space.”
BackgroundZeng, Z., Liu, Y., Zheng, W., Liu, L., Yin, H., Zhang, S., Bai, H., Hua, L., Wang, S., Wang, Z., et al. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1669388 · Cited by 48
“The relative transcriptional levels of target genes were computed by 2 method [2].”
BackgroundMethodInfluentialRetractedCrehan, H., Liu, B., Kleinschmidt, M., Rahfeld, J., Le, K. X., Caldarone, B. J., Frost, J. L., Hettmann, T., Hutter‐Paier, B., O’Nuallain, B., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0579-8 · Cited by 50
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 51
“Aducanumab Antibody Aβ aggregates, including oligomers and fibrils Autoantibody-derived antibody that binds Aβ oligomers and fibrils and reduces insoluble amyloid plaques [68,200]; under FDA review for approval”
BackgroundAdvances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 47
Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., McLean, C., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2021) · Brain Communications · doi:10.1093/braincomms/fcab028 · Cited by 54
Amyloid β 42 fibril structure based on small-angle scattering
Lattanzi, V., André, I., Gasser, U., Dubackic, M., Olsson, U., & Linse, S. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112783118 · Cited by 52
“While no effective treatments are currently available (14), the Food and Drug Administration (FDA) recently approved (18) the antibody Aducanumab, which reduces brain amyloid load as well as clinical symptoms (19, 20) and inhibits the generation of toxic oligomers through surface-catalyzed nucleation (21).”
BackgroundInfluentialThe Problem of Aducanumab for the Treatment of Alzheimer Disease
Alexander, G. C., & Karlawish, J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2603 · Cited by 47
“Aducanumab's phase 1 study indicates the drug reduces b-amyloid levels (4).”
BackgroundPersonalized risk for clinical progression in cognitively normal subjects-the ABIDE project
Initiative, F. T. A. D. N., van Maurik, I. S., Slot, R. E. R., Verfaillie, S. C. J., Zwan, M. D., Bouwman, F. H., Prins, N. D., Teunissen, C. E., Scheltens, P., Barkhof, F., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0487-y · Cited by 47
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.